TMCnet News
Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1536 at the 2019 American Society of Clinical Oncology Annual MeetingCAMBRIDGE, Mass., May 20, 2019 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will present interim data from the ongoing Phase 1 dose-escalation study evaluating XMT-1536, its first-in-class ADC candidate targeting NaPi2b, in patients with ovarian cancer, non-small cell lung (NSCLC) adenocarcinoma and other rare tumor types. The data will be presented in a poster session and poster discussion at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting being held from May 31 – June 4, 2019 in Chicago, IL. Details of the poster display and discussion are as follows: Poster Title: Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjgate (ADC), in patients (pts) with solid tumors likely to express NaPi2b. Date: June 1, 2019 Poster Display: 8:00 AM – 11:00 AM C.T., Location – Hall A, Poster Board #2 Poster Discussion: 3:00 PM – 3:22 PM C.T., Location – E450 Session: Developmental Therapeutics and Tumor Biology (Nonimmuno) About Mersana Therapeutics Contact: Investor Contact Media Contact
|